Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Net Cash Flow (2023 - 2025)

Mangoceuticals' Net Cash Flow history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 14311.36% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 293.15% increase, with the full-year FY2025 number at $1.4 million, up 311.87% from a year prior.
  • Net Cash Flow hit $1.0 million in Q4 2025 for Mangoceuticals, up from $380307.0 in the prior quarter.
  • Over the last five years, Net Cash Flow for MGRX hit a ceiling of $3.2 million in Q1 2023 and a floor of -$1.7 million in Q3 2023.
  • Historically, Net Cash Flow has averaged $61769.8 across 3 years, with a median of $1571.0 in 2024.
  • Biggest five-year swings in Net Cash Flow: tumbled 122.7% in 2024 and later surged 14311.36% in 2025.
  • Tracing MGRX's Net Cash Flow over 3 years: stood at -$497741.0 in 2023, then surged by 98.58% to -$7077.0 in 2024, then surged by 14311.36% to $1.0 million in 2025.
  • Business Quant data shows Net Cash Flow for MGRX at $1.0 million in Q4 2025, $380307.0 in Q3 2025, and $24336.0 in Q2 2025.